Profile image
Story Views

Last Hour:
Last 24 Hours:

Neprilysin Therapeutics Industry Pipeline Review H2 2016 with Detail Drugs Profile and Top Players Analysis

Thursday, November 3, 2016 4:27
% of readers think this story is Fact. Add your two cents.

Latest Neprilysin Pipeline Review, H2 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

Neprilysin therapeutics industry report provides comprehensive information on the therapeutics under development for Neprilysin, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neprilysin and features dormant and discontinued projects.

Browse more detail information about Neprilysin market report at:

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Neprilysin – Pipeline Review, H2 2016:

  • Bioprojet SCR
  • Novartis AG
  • Pharmaleads SA
  • Theravance Biopharma, Inc.

Get a PDF Sample of Neprilysin Market Research Report at:


Drug Profiles of Included in Neprilysin Therapeutics Development Market Report

  • dexecadotril
  • PL-265
  • STR-324
  • TD-0714

And other drug profiles
Have any query? ask our expert @

Key Topics Covered:
2.Neprilysin Overview
3.Neprilysin Therapeutics Development
4.Pipeline Products for Neprilysin – Overview
5.Pipeline Products for Neprilysin – Comparative Analysis
6.Neprilysin – Therapeutics under Development by Companies
7.Neprilysin – Therapeutics under Investigation by Universities/Institutes
8.Neprilysin Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Neprilysin – Products under Development by Companies
13.Neprilysin – Products under Investigation by Universities/Institutes
14.Neprilysin – Companies Involved in Therapeutics Development
15.Neprilysin Drug Profiles
16.Neprilysin Dormant Projects
17.Neprilysin Discontinued Products
18.Neprilysin Featured News & Press Releases

19.R&D Progress

Sep 19, 2016: Important new analysis shows that Novartis Entresto is associated with higher relative health-related quality of life scores among HFrEF patients

Jun 22, 2016: Timely use of Novartis Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology

Jun 09, 2016: New Review of PARADIGM-HF Results: LCZ696, an Angiotensin-neprilysin Inhibitor, Versus Enalapril in Heart Failure

May 21, 2016: Novartis’ Entresto given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals

May 19, 2016: Novartis announces investment in FortiHFy clinical program of Entresto and heart failure

Apr 26, 2016: NICE gives green light to new drug set to benefit 100,000 people with common heart condition

Apr 02, 2016: New analyses show Novartis’ Entresto reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless

Mar 09, 2016: Theravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Study of TD-0714, an Inhibitor of Neprilysin
And Continue…

Get Discount on Neprilysin Market Research Report at:

This 57 pages research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neprilysin
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neprilysin pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email –

We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.